UroGen Pharma (URGN) Cash from Financing Activities (2017 - 2026)
UroGen Pharma's (URGN) quarterly Cash from Financing Activities came in at $65.2 million in Q1 2026, up 191676.47% YoY from N/an in Q1 2025, and up 108.21% on a QoQ basis from $31.3 million in Q4 2025.
UroGen Pharma (URGN) Cash from Financing Activities (2017 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 10 years of Cash from Financing Activities data on file, last reported at $65.2 million in Q1 2026.
- Quarterly Cash from Financing Activities rose 191676.47% year-over-year to $65.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $105.1 million (down 24.93% YoY) and the FY2025 annual result came in at $39.9 million, down 79.49% from the prior year.
- Cash from Financing Activities grew to $65.2 million in Q1 2026, from $31.3 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $116.1 million in Q3 2023 to a low of -$77000.0 in Q2 2022.
- A 5-year average of $30.2 million and a median of $8.3 million in 2025 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 1768450.0% in 2022, down 100.11% in 2022.
- Tracing URGN's Cash from Financing Activities over 5 years: stood at $25.4 million in 2022, then slumped by 99.84% to $40000.0 in 2023, then surged by 77.5% to $71000.0 in 2024, then surged by 44007.04% to $31.3 million in 2025, then surged by 108.21% to $65.2 million in 2026.
- The last three Cash from Financing Activities figures came in at $65.2 million (Q1 2026), $31.3 million (Q4 2025), and $8.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn | 500,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 500,000.00 |
| Jun 30, 2026 | 500,000.00 |
| Mar 31, 2026 | 65.20 Mn |
| Mar 31, 2026 | 65.20 Mn |
| Dec 31, 2025 | 31.32 Mn |
| Dec 31, 2025 | 31.32 Mn |
| Sep 30, 2025 | 8.27 Mn |
| Sep 30, 2025 | 8.27 Mn |
| Jun 30, 2025 | 296,000.00 |
| Jun 30, 2025 | 296,000.00 |
| Mar 31, 2025 | 34,000.00 |
| Mar 31, 2025 | 34,000.00 |
| Dec 31, 2024 | 71,000.00 |
| Dec 31, 2024 | 71,000.00 |
| Sep 30, 2024 | 39.61 Mn |
| Sep 30, 2024 | 39.61 Mn |
| Jun 30, 2024 | 100.29 Mn |
| Jun 30, 2024 | 100.29 Mn |
| Mar 31, 2024 | 54.66 Mn |
| Mar 31, 2024 | 54.66 Mn |